Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
READ MORE...
Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections
READ MORE...
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
READ MORE...
Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors
READ MORE...
Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts
READ MORE...
Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral
READ MORE...
Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
READ MORE...
Pneumagen Announces Appointment of John Beadle as Non-Executive Director
READ MORE...
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
